Skip to content
Blackberry Empire – Lifestyle
Author:
ZHEJIANG WENDA PHARMACEUTICAL TECHNOLOGY CO., LTD.
Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
October 27, 2026
China Innovative Drug NHWD-870 Receives Breakthrough Therapy Designation, Bringing New Hope of Survival to NUT Carcinoma Patients
May 11, 2026